When to biopsy and when to stop biopsying

Area of Science:

• Urologic Oncology
• Diagnostic Accuracy in Prostate Cancer

Background:

• Serum prostate-specific antigen (PSA) testing and transrectal ultrasound-guided (TRUS) prostate biopsies are standard for diagnosing prostate cancer.
• Physicians often encounter diagnostic challenges with suspected prostate cancer despite initial negative biopsy results.
• The optimal number of biopsy cores for initial prostate cancer detection remains a subject of debate.

Purpose of the Study:

• To address the clinical dilemma of managing patients with a high suspicion of prostate cancer following initial negative biopsies.
• To investigate the controversy surrounding the optimal number of biopsy cores for initial prostate cancer detection.
• To provide guidance on repeat prostate biopsy indications and cessation criteria.

Main Methods:

• Review of current literature and clinical guidelines on prostate biopsy protocols.
• Analysis of factors influencing prostate cancer detection rates based on biopsy core number.
• Evaluation of criteria for recommending repeat prostate biopsies in suspicious cases.

Main Results:

• The optimal number of biopsy cores for initial prostate cancer detection is not definitively established and varies among guidelines.
• Repeat biopsies are often indicated in cases of persistently elevated PSA or suspicious imaging findings, even after initial negative results.
• Clear criteria for when to stop further biopsies are often lacking, leading to potential overtreatment or undertreatment.

Conclusions:

• The optimal number of initial prostate biopsy cores requires further research to balance detection rates and patient burden.
• Clinical decision-making for repeat prostate biopsies should integrate PSA kinetics, imaging, and patient factors.
• Standardized guidelines are needed to clarify when to cease prostate biopsy procedures to avoid unnecessary interventions.